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PAntiplatelet Therapy
Patients With Poor Responsiveness to
Thienopyridine Treatment or With Diabetes Have Lower
Levels of Circulating Active Metabolite, but Their Platelets
Respond Normally to Active Metabolite Added Ex Vivo
David Erlinge, MD, PHD,* Christoph Varenhorst, MD,† Oscar Ö. Braun, MD, PHD,*
Stefan James, MD, PHD,† Kenneth J. Winters, MD,§ Joseph A. Jakubowski, PHD,§
John T. Brandt, MD,§ Atsuhiro Sugidachi, PHD, Agneta Siegbahn, MD, PHD,‡
Lars Wallentin, MD, PHD†
Lund and Uppsala, Sweden; Indianapolis, Indiana; and Tokyo, Japan
Objectives We evaluated the prevalence and mechanism of poor responsiveness to clopidogrel and prasugrel in coronary
artery disease patients with and without diabetes.
Background Low platelet inhibition by clopidogrel is associated with ischemic clinical events. A higher 600-mg loading dose
(LD) has been advocated to increase responsiveness to clopidogrel.
Methods In this study, 110 aspirin-treated patients were randomized to double-blind treatment with clopidogrel 600 mg
LD/75 mg maintenance dose (MD) for 28 days or prasugrel 60 mg LD/10 mg MD for 28 days. Pharmacody-
namic (PD) response was evaluated by light transmission aggregometry and vasodilator-stimulated phosphopro-
tein phosphorylation. The PD poor responsiveness was defined with 4 definitions previously associated with
worse clinical outcomes. Active metabolites (AM) of clopidogrel and prasugrel were measured. Clopidogrel AM
was added ex vivo.
Results The proportion of patients with poor responsiveness was greater in the clopidogrel group for all definitions at all
time points from 1 h to 29 days. Poor responders had significantly lower plasma AM levels compared with re-
sponders. Patients with diabetes were over-represented in the poor-responder groups and had significantly lower
levels of AM. Platelets of both poor responders and diabetic patients responded fully to AM added ex vivo.
Conclusions Prasugrel treatment results in significantly fewer PD poor responders compared with clopidogrel after a 600-mg
clopidogrel LD and during MD. The mechanism of incomplete platelet inhibition in clopidogrel poor-responder
groups and in diabetic patients is lower plasma levels of its AM and not differences in platelet P2Y12 receptor
function. (J Am Coll Cardiol 2008;52:1968–77) © 2008 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2008.07.068i
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ia antagonism of the P2Y12 receptor and have been used
uccessfully to prevent thrombotic events in patients with
cute coronary syndromes and in patients undergoing stent
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ccepted July 10, 2008.mplantation (1,2). Since the first report of a variable
esponse to clopidogrel (3), many studies have shown a high
revalence of patients with pharmacodynamic (PD) poor
esponsiveness to clopidogrel using a large number of
See page 1978
efinitions (4–13). The most relevant definitions of PD
oor responders are those that have been associated with
orse clinical outcomes. In the literature at least 4 defini-
ions of insufficient platelet inhibition (poor responders) by
lopidogrel have been linked to clinical end points: 1)
hange in maximal platelet aggregation (MPA) 10%
ssociated with post-percutaneous coronary intervention
PCI) myonecrosis (5–7); 2) MPA 50% associated with
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December 9, 2008:1968–77 Thienopyridine Respondersost-procedural ischemic events 1 year after PCI (8–10); 3)
esidual platelet aggregation (RPA) at 6 min14% linked to
0-day major adverse cardiac events post-PCI (14); and 4)
latelet reactivity index (PRI) with vasodilator-stimulated
hosphoprotein (VASP) 50% linked to subacute stent
hrombosis (13,15,16). Furthermore, diabetic patients have
onsistently been shown to be poor responders to clopidogrel,
ith worse clinical outcomes (1,2,17–19). The mechanisms for
he poor response to clopidogrel in some patients are unclear,
lthough genetic, metabolic, cellular, and clinical factors have
een proposed (20). More recent work suggests that reduced
eneration of active metabolite (AM) may contribute to
lopidogrel poor responsiveness (21).
We recently examined the effect of 60-mg prasugrel
ompared with a 600-mg clopidogrel loading dose (LD)
nd found a faster onset and greater platelet inhibition with
rasugrel treatment because of more efficient generation of
ts AM (22). Prasugrel 60 mg, compared with 300-mg
lopidogrel, reduces the number of poor responders accord-
ng to a Bayesian definition of poor responders (23). A
00-mg clopidogrel LD has been advocated to decrease
lopidogrel response variability.
The aims of the present study were to use previously
ublished clinically relevant definitions of low PD platelet
nhibition to: 1) determine the number of PD poor respond-
rs to a clopidogrel 600-mg LD and 75-mg maintenance
ose (MD) compared with a prasugrel 60-mg LD followed
y 10-mg MD; 2) evaluate the PD poor-responder groups
y characterization of the pharmacokinetics of clopidogrel
nd prasugrel AMs; and 3) examine P2Y12 receptor func-
ion in PD poor responders by the addition of the clopi-
ogrel AM ex vivo.
ethods
atients and study design. This randomized, double-
lind, double-dummy, 2-arm, parallel-group study was
onducted in adult male and female patients with stable
oronary artery disease, ages 40 to 75 years (Fig. 1). The
etailed protocol and main results have been published
lsewhere (22). All patients were administered an LD of
ither prasugrel 60 mg or clopidogrel 600 mg on Day 1
ollowed by either prasugrel 10 mg or clopidogrel 75 mg as
once-daily MD for a total of 28  3 days. On Days 1 and
, 14 3, and 29 3, study medications were administered
t the study site after an overnight fast.
D analyses. LIGHT TRANSMISSION AGGREGOMETRY
LTA). The adenosine 5=-diphosphate (ADP)-induced
latelet aggregation was measured in platelet-rich plasma by
TA on Day 1 at baseline (pre-dose); 30 min, 60 min, 2 h,
h, and 24  4 h post-LD; Day 14  3; and Day 29  3.
he LTA was performed within 180 min from venipunc-
ure on a BioData PAP-4 optical aggregometer (Alpha
aboratories, Eastleigh, United Kingdom), with tempera-ure maintained at 37°C and using each subject’s platelet- aoor plasma to set 100% light
ransmission. Platelet aggrega-
ion was allowed to proceed for
pproximately 7 min after addi-
ion of 5-M ADP. The MPA
as the highest value achieved
uring this observation period.
n addition, the mean change
rom baseline (pre-LD) in MPA
MPA) was calculated for each
ime point and used for statistical
nalyses. The RPA was the level
f platelet aggregation present at
min after addition of the ADP
gonist. The ADP concentration
sed was 5 M for MPA
10%, MPA 50% and RPA
14%.
ASP PHOSPHORYLATION. The
ASP phosphorylation assay was
erformed using a commercially
vailable method according to
he manufacturer’s specifications
Biocytex Platelet VASP kit, Marseille, France). The VASP
ssay is a commercial kit in which the concentration of ADP
s not disclosed.
harmacokinetic analyses. CONCENTRATION OF AM.
lasma concentrations of prasugrel AM (R-138727) and
lopidogrel AM (R-130964) were analyzed in samples
btained at 30 min and 1, 2, 4, and 6 h post-LD, during
he MD period on Day 2 pre-MD, and on Days 14 and
9 at 30 min and 1, 2, and 4 h post-MD as previously
escribed (22).
DDITION OF CLOPIDOGREL AM EX VIVO. The AM of
lopidogrel (10-M final concentration; provided by Daii-
hi Sankyo Co., Ltd., Tokyo, Japan) was added ex vivo to
amples collected at baseline (pre-LD) and pre-dosed on
ay 29 as previously described (22,24).
tatistical analyses. The geometric mean area under the
urve (AUC) for the AM, with the corresponding 95%
onfidence limits, was calculated for the PD poor and good
esponder groups, respectively, after LD and during MD.
ifferences between groups were evaluated using the Stu-
ent t test. The values of the AUC were transformed to
atural logarithms before analyses. Similar analyses were
erformed for diabetic compared with nondiabetic pa-
ients after LD and during MD. Differences between
roups were evaluated with analysis of variance adjusted
or treatment. Ex vivo LTA and VASP data from the ex
ivo addition of clopidogrel AM experiment were ana-
yzed to compare the platelet response in treated and
ntreated samples from the same individual. Differences
etween groups were evaluated with an analysis of vari-
Abbreviations
and Acronyms
ADP  adenosine
5’-diphosphate
AM  active metabolite
AUC  area under the
curve
LD  loading dose
LTA  light transmission
aggregometry
MD  maintenance dose
MPA  maximal platelet
aggregation
PCI  percutaneous
coronary intervention
PD  pharmacodynamic
PRI  platelet reactivity
index
RPA  residual platelet
aggregation
VASP  vasodilator-
stimulated phosphoproteinnce model compensating for treatment. Differences in
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Thienopyridine Responders December 9, 2008:1968–77he relative number of diabetic patients in the poor-
esponder compared with good-responder groups were
valuated with Cochran-Mantel-Haenszel statistics com-
ensating for treatment. The software used for statistical
nalyses was SAS version 9.1 (SAS Institute Inc., Cary,
orth Carolina).
esults
atients. A total of 110 subjects (55 in each arm) were
nrolled in the study (101 men and 9 women), and 106 subjects
ompleted the study: 54 on prasugrel and 52 on clopidogrel
Fig. 1).
roportion of poor responders according to 4 clinically
elevant definitions of poor responders. The proportion
f patients with PD poor responsiveness varied between
.6% and 92.5% in the clopidogrel-treated patients, de-
ending on definitions and time after thienopyridine LD,
espite the high 600-mg clopidogrel LD (Fig. 2A, Table 1). In
ontrast, the proportion of patients with poor responsiveness
aried between 0% and 16.4% in the prasugrel-treated patients,
epending on definitions and time after thienopyridine LD
Figure 1 Study Design
A 2-center, randomized, double-blind, double-dummy study in
patients ages 40 to 75 years with stable coronary artery disease.Fig. 2A, Table 1). Similar results were found during theD phase at pre-dose on Day 29 thienopyridine MD (Fig.
B, Table 1). During MD the number of clopidogrel poor
esponders varied between 15% and 53% using the MPA
10%, MPA 50%, or VASP PRI 50% definitions,
hereas the prasugrel poor responders varied between 2%
nd 4%. The RPA 14% definition resulted in the highest
umber of PD poor responders, up 63% to 72% for
lopidogrel and 22% to 28% for prasugrel. The propor-
ion of patients with PD poor responsiveness was greater
n the clopidogrel group compared with prasugrel-treated
atients for all tested definitions both following LD and
uring MD.
harmacokinetics of AM after oral administration of
tudy drug. For all 4 definitions of poor response, patients
efined as PD poor responders at 2 h after the clopidogrel
D had a significantly lower AM AUC than did patients
ho were PD responders: MPA 10% 0.160  0.057
M·h versus 0.263  0.028 M·h, p  0.01; MPA 50%
.186  0.041 M·h versus 0.264  0.035 M·h,
Figure 2 Proportion of PD Poor Responders According to
Definitions Associated With Poor Clinical Outcomes
(A) Poor responders at 2 h after thienopyridine LD. (B) Poor responders at Day
29 after thienopyridine MD. The solid bars represent patients treated with pra-
sugrel 60-mg LD/10-mg MD and the open bars represent patients treated with
clopidogrel 600-mg LD/75-mg MD. The ADP concentration used was 5 M for
MPA 10%, MPA 50%, and RPA 14%. The VASP assay is a commercial
kit in which the concentration of ADP is not disclosed. LD  loading dose;
MD  maintenance dose; MPA  maximal platelet aggregation; PD  pharma-
codynamic; PRI  platelet reactivity index; RPA  residual platelet aggregation;
VASP  vasodilator-stimulated phosphoprotein.
p
0

r
c
s
P
0

0
V
0
r
p
o
I
a
r
P
V
L
W
(
b
T
t
f
P
M
a
g
T
d
p
g
f
i
(
a
t
d
m
P
s
w
i
S
p
l
(
t
I
a
W
w
h
t
(
p
m
c
p
t
(
w
w
R
i
R
V
d
s
D
T
t
p
d
t
P
T rdless
rmacod
1971JACC Vol. 52, No. 24, 2008 Erlinge et al.
December 9, 2008:1968–77 Thienopyridine Responders 0.01; RPA14% 0.219 0.029 M·h versus 0.277
.065 M·h, p  0.05; VASP (PRI) 50% 0.201  0.029
M·h versus 0.297  0.046 M·h, p  0.01 (poor
esponders vs. good responders respectively) (Fig. 3A).
Likewise, patients defined as PD poor responders to
lopidogrel, based on the Day 29 MD PD response, had
ignificantly lower clopidogrel AM AUC after MD than did
D responders: MPA 10% 0.045  0.013 M·h versus
.067 0.018 M·h, p 0.01; MPA50% 0.049 0.011
M·h versus 0.068  0.009 M·h, p  0.01; RPA 14%
.057 0.007 M·h versus 0.072 0.0017 M·h, p 0.05;
ASP (PRI) 50% 0.049  0.0008 M·h versus 0.074 
.01 M·h, p  0.01 (poor responders vs. good responders
espectively) (Fig. 3B).
The number of PD poor responders in the prasugrel-treated
atients was small in most groups, and a statistical comparison
f AM levels therefore was not possible.
nhibition of P2Y12 receptors evaluated by the VASP
ssay at baseline and after addition of AM ex vivo in poor
esponders compared with responders. Inhibition of
2Y12 receptors is more specifically assessed with the
ASP phosphorylation assay because, in contrast to
TA, effects on the P2Y1ADP receptor are not detected.
e therefore compared the PD poor-responder group
defined as VASP PRI 50%) to the responder group at
aseline and after ex vivo addition of the clopidogrel AM.
here was no difference in PRI (%) at baseline, indicating
hat the groups did not differ in baseline P2Y12 receptor
unction. There also was no difference in the reduction of
RI (%) after addition of AM either before LD or during
D, indicating that the P2Y12 receptor function and
ffinity for the AM is similar for poor responders and
ood responders (Fig. 4).
he numbers of diabetic patients in 4 clinically relevant
efinitions of poor responders. Ten patients in the
rasugrel-treated group and 9 in the clopidogrel-treated
roup were previously diagnosed as having diabetes. The
raction of patients with diabetes was consistently higher
n all 4 definitions of poor responders at all time points
Table 2). Diabetic patients were significantly over-represented
mong PD poor-responder patients at most of the treatment
roportion of PD Poor Responders According to Definitions Associa
Table 1 Proportion of PD Poor Responders According to Definit
Time
MPA <10%,
% Poor Responders (n)
MPA >50%,
% Poor Responder
Clopidogrel Prasugrel Clopidogrel P
LD, 1 h 43.4 (23) 3.7 (2) 66.0 (35)
LD, 2 h 19.2 (10) 0 (0) 28.9 (15)
LD, 4 h 9.6 (5) 0 (0) 25.0 (13)
LD, 24 h 15.1 (8) 0 (0) 26.4 (14)
MD, Day 14 15.1 (8) 1.9 (1) 26.4 (14)
MD, Day 29 21.2 (11) 1.9 (1) 28.9 (15)
he number of poor responders was higher in the clopidogrel-treated group at all time points rega
LD  loading dose; MD  maintenance dose; MPA  maximal platelet aggregation; PD  phaime points (evaluated with Cohran-Mantel-Haenszels test, ciabetes mellitus vs. nondiabetes mellitus, adjusted for treat-
ent number of patients in subgroups).
harmacokinetics of AM after oral administration of
tudy drugs in diabetic patients. Compared with patients
ithout diabetes, there was a trend toward a lower AM AUC
n diabetic patients taking clopidogrel or prasugrel (Fig. 5).
tatistical evaluation of all clopidogrel- and prasugrel-treated
atients, with compensation for treatment, yielded significantly
ower levels of AM in patients with diabetes at post-LD 2 h
p 0.0064) and at MD Day 29 (p 0.0047) compared with
hose without diabetes.
nhibition of P2Y12 receptors evaluated by the VASP
ssay in diabetic compared with nondiabetic patients.
e examined PRI (%) in the diabetic patients compared
ith nondiabetic patients. There was a trend toward
igher PRI (%) in both clopidogrel- and prasugrel-
reated diabetic patients, both after LD and during MD
Fig. 6). Statistical evaluation of all clopidogrel- and
rasugrel-treated patients, using an analysis of variance
odel compensating for treatment, showed a signifi-
antly higher PRI (%) for the thienopyridine treatment in
atients with diabetes compared with nondiabetic pa-
ients both at 2 h post-LD (p  0.01) and MD Day 29
p  0.02). However, no statistical difference or trend
as seen at baseline or at the 2 time points at which AM
as added (Fig. 6).
egression analysis for AM (AUC) versus VASP reactiv-
ty index (PRI%) in poor-responder subjects defined as
PA >14%. Regression analysis for AM (AUC) versus
ASP reactivity index (PRI%) in poor-responder subjects
efined as RPA 14% at MD Day 29 showed a linear and
ignificant correlation (p  0.001) (Fig. 7).
iscussion
his study shows that, compared with clopidogrel, prasugrel
reatment results in a lower proportion of patients with a
oor response using 2 distinct PD assays and several
ifferent definitions of PD poor responder previously linked
o worse clinical outcomes. The PD poor responders were
ith Clinical Outcomes
Associated With Clinical Outcomes
RPA >14%,
% Poor Responders (n)
PRI >50%,
% Poor Responders (n)
el Clopidogrel Prasugrel Clopidogrel Prasugrel
) 92.5 (49) 16.4 (8) 83.0 (44) 9.1 (5)
) 63.5 (34) 1.9 (1) 56.6 (30) 1.8 (1)
) 51.9 (27) 1.9 (1) — —
) 60.4 (32) 3.6 (2) 58.5 (31) 0 (0)
) 71.7 (38) 22.2 (12) 52.8 (28) 1.8 (1)
) 63.5 (33) 27.8 (15) 45.3 (24) 3.6 (2)
of definition of poor responsiveness.
ynamic; PRI  platelet reactivity index; RPA  residual platelet aggregation.ted W
ions
s (n)
rasugr
9.1 (5
0 (0
0 (0
1.8 (1
1.9 (1
1.9 (1onsistently fewer in the prasugrel-treated patient group
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Thienopyridine Responders December 9, 2008:1968–77fter LD and during MD despite comparison with the
igher 600-mg clopidogrel LD. We found that both PD
Figure 3 Plasma Concentration of Active Metabolite During LD
(A) Active metabolite (AUC) for prasugrel- and clopidogrel-treated patients determin
(AUC) for prasugrel- and clopidogrel-treated patients determined to be responders
y axis. The ADP concentration used was 5 M for MPA 10%, MPA 50%, and
not disclosed. AUC  area under the curve; other abbreviations as in Figure 2.oor responders and diabetic patients had relatively lower cevels of circulating AM. However, the platelets from both
oor responders and diabetic patients responded fully to the
MD
be responders or poor responders 2 h after either LD. (B) Active metabolite
r responders at 29 days after either MD. Please note the different scales on the
14%. The VASP assay is a commercial kit in which the concentration of ADP isand
ed to
or poo
RPA lopidogrel AM added ex vivo.
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December 9, 2008:1968–77 Thienopyridine RespondersA poor response to thienopyridines has been shown to be
linically important, associated with coronary ischemic
vents and stent thrombosis, which in turn are associated
ith long-term mortality (4–13,25). We therefore exam-
Figure 4 Inhibition of P2Y12 Receptor Function Measured by
VASP Assay on Addition of Clopidogrel AM
Inhibition of P2Y12 receptors determined by the VASP assay in responder and
poor responder groups (defined as PRI 50%): 1) at baseline before addition
of clopidogrel AM; 2) at baseline after the addition of the clopidogrel AM to
each group; and 3) at Day 29 of MD after the addition of the clopidogrel AM to
each group. AM  active metabolite; PRI  platelet reactivity index; other
abbreviations as in Figure 2.
elative (%) and Absolute Numbers (n) of Diabetic Patients Among
Table 2 Relative (%) and Absolute Numbers (n) of Diabetic Pat
Definition of
Poor Responder Time
Clopidogrel No DM
% (n)
MPA 10% to 5-M ADP LD, 1 h 37.8 (17)
LD, 2 h 18.2 (8)
LD, 4 h 6.8 (3)
LD, 24 h 11.1 (5)
MD, Day 14 11.1 (5)
MD, Day 29 15.9 (7)
MPA 50% to 5-M ADP LD, 1 h 62.2 (28)
LD, 2 h 22.7 (10)
LD, 4 h 20.5 (9)
LD, 24 h 20.0 (9)
MD, Day 14 22.2 (10)
MD, Day 29 25.0 (11)
RPA 14% to 5-M ADP LD, 1 h 91.1 (41)
LD, 2 h 56.8 (25)
LD, 4 h 45.5 (20)
LD, 24 h 55.6 (25)
MD, Day 14 68.9 (31)
MD, Day 29 59.1 (26)
PRI 50% VASP LD, 1 h 80.0 (36)
LD, 2 h 51.1 (23)
LD, 24 h 53.3 (24)
MD, Day 14 46.7 (21)
MD, Day 29 40.0 (18)
oor responders were defined according to 4 definitions previously associated with clinical outcom
oints. The p value was analyzed in the whole population regardless of treatment.
ADP  adenosine 5’-diphosphate; DM  diabetes mellitus; other abbreviations as in Table 1.ned the prevalence of PD poor responders to thienopyri-
ines in aspirin-treated patients with stable coronary artery
isease. We used 2 different assays and 4 different PD
efinitions of poor responders that all have previously been
hown to be associated with an increase in ischemic coro-
ary events. Prasugrel treatment consistently resulted in few
D poor responders according to any of the 4 definitions
uring the whole 1-month treatment period (Fig. 2, Table
). During maintenance dosing the number of clopidogrel
oor responders varied between 15% and 53% using the
MPA 10%, MPA 50%, or VASP PRI 50% defini-
ions, whereas the prasugrel poor responders varied between
% and 4%. The RPA 14% definition resulted in the
ighest number of PD poor responders, from 63% to 72%
or clopidogrel and 22% to 28% for prasugrel.
In the clinical situation, it is important to rapidly achieve
latelet inhibition when a patient with an acute coronary
yndrome is to be treated in the PCI laboratory. A 600-mg
lopidogrel dose has been shown to achieve a more rapid
latelet inhibition compared with 300 mg (26). In the
resent study, despite the use of the higher 600-mg LD,
lopidogrel resulted in PD poor-responder rates between
9% and 92% during the first 2 h after the LD. In
ontrast, a 60-mg prasugrel LD resulted in poor-
esponder rates between 0% and 16%. The reduced
umber of PD poor responders on prasugrel is likely an
r Responders
Among Poor Responders
opidogrel DM
% (n)
Prasugrel No DM
% (n)
Prasugrel DM
% (n) p Value
75.0 (6) 0.0 (0) 18.2 (2) 0.004
25.0 (2) 0.0 (0) 0.0 (0) 0.656
25.0 (2) 0.0 (0) 0.0 (0) 0.112
37.5 (3) 0.0 (0) 0.0 (0) 0.057
37.5 (3) 0.0 (0) 9.1 (1) 0.012
50.0 (4) 0.0 (0) 9.1 (1) 0.007
87.5 (7) 6.8 (3) 18.2 (2) 0.073
62.5 (5) 0.0 (0) 0.0 (0) 0.024
50.0 (4) 0.0 (0) 0.0 (0) 0.079
62.5 (5) 0.0 (0) 9.1 (1) 0.003
50.0 (4) 0.0 (0) 9.1 (1) 0.029
50.0 (4) 0.0 (0) 9.1 (1) 0.048
100.0 (8) 13.6 (6) 27.3 (3) 0.168
100.0 (8) 0.0 (0) 9.1 (1) 0.005
87.5 (7) 0.0 (0) 10.0 (1) 0.008
87.5 (7) 2.3 (1) 9.1 (1) 0.048
87.5 (7) 20.9 (9) 27.3 (3) 0.289
87.5 (7) 25.6 (11) 36.4 (4) 0.119
100.0 (8) 9.1 (4) 9.1 (1) 0.300
87.5 (7) 2.3 (1) 0.0 (0) 0.096
87.5 (7) 0.0 (0) 0.0 (0) 0.073
87.5 (7) 0.0 (0) 9.1 (1) 0.009
75.0 (6) 2.3 (1) 9.1 (1) 0.037
tic patients were over-represented among poor responsive patients at most of the treatment timePoo
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Thienopyridine Responders December 9, 2008:1968–77mportant factor for the reduced rates of ischemic events,
ncluding significant reductions in stent thrombosis,
hown for prasugrel during both the acute and the MD
hases of the TRITON (Trial to Assess Improvement in
herapeutic Outcomes by Optimizing Platelet Inhibition
ith Prasugrel–Thrombolysis In Myocardial Infarction)
tudy (2).
Although several studies have shown that definitions of
D poor responders to clopidogrel are associated with worse
linical outcomes, the physiological differences resulting in
he poor response in patients has not been fully elucidated.
Figure 5 Plasma Concentration of AM by Diabetic Status
Exposure to each AM after administration of study drug by diabetic status.
(A) The AUC of clopidogrel AM in diabetic patients compared with nondiabetic
patients after clopidogrel treatment. (B) The AUC of prasugrel AM in diabetic
patients compared with nondiabetic patients after prasugrel treatment. Data
presented as mean  95% confidence interval. Abbreviations as in Figures 2
to 4.enetic alterations in the P2Y12 gene resulting in functionalifferences have been found (27), but they have not been
onfirmed by others (28,29), and when we recently exam-
ned the incidence of myocardial infarction and risk factors
n over 10,000 patients, we did not find any genetic
ssociation with the P2Y12 receptor (30). Statin coadmin-
stration has not been confirmed as a factor in clopidogrel
esistance (31). Instead, a correlation between plasma con-
entrations of AM and the level of ADP inhibition has been
hown (21,22).
Regardless of the definition used, all PD poor-responder
roups in our study had lower levels of circulating AM. This
as true not only in the mixed group of clopidogrel- and
rasugrel-treated patients but also in the patients treated
nly with clopidogrel (Fig. 3). Thus, PD poor responders
re defined by reduced generation of AM. This strongly
uggests that the clinically at-risk poor-responder patients
ost likely differ in their absorption of pro-drug or their
Figure 6
Inhibition of P2Y12 Receptor
Function Measured by VASP Assay
on Addition of Clopidogrel AM by Diabetic Status
Inhibition of P2Y12 receptors evaluated by VASP in diabetic compared with non-
diabetic patients before and after ex vivo addition of the clopidogrel AM in clo-
pidogrel-treated patients (A) and prasugrel-treated patients (B). Data pre-
sented as mean  95% confidence interval. *p  0.05 for diabetic patients
for the combined group of clopidogrel- and prasugrel-treated patients. Abbrevia-
tions as in Figures 2 and 4.
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December 9, 2008:1968–77 Thienopyridine Respondersetabolic profile regarding conversion of the pro-drug to
he AM. In this regard, there is evidence that variation in
he gene encoding cytochrome P450 2C19 that results in
ecreased 2C19 function is associated with decreased for-
ation of the AM of clopidogrel and a corresponding
ecrease in the PD response to clopidogrel (32).
There was a clear linear correlation between circulating
M (AUC) versus the VASP reactivity index (PRI%) in
oor-responder subjects defined as RPA 14% (Fig. 7).
his indicates that the level of AM is crucial for platelet
nhibition even within the group of poor responders.
However, a difference in platelet function or receptor
ffinity for the antagonist could also explain the poor
esponders. To examine the P2Y12 receptor function with-
ut confounding effects of the P2Y1 receptor, we used the
ASP assay (33). Baseline responsiveness to ADP did not
iffer between PD poor responders and responders, exclud-
ng a generally higher level of platelet reactivity as an
xplanation for poor response to thienopyridine treatment.
urthermore, addition of AM ex vivo gave a similar near
aximal inhibition in both groups, suggesting that the
2Y12 receptor-antagonist interactions are unaffected in
oor responders.
Angiolillo et al. (17,18) have shown that patients with
iabetes mellitus have a higher number of clopidogrel
onresponders and a reduced sensitivity to clopidogrel, and
hat high platelet reactivity in diabetic patients (MPA
50%) on dual antiplatelet therapy is associated with a
Figure 7 Analysis of Plasma Concentration and Percent PRI in
Scatter plot and regression analysis for AM (AUC) versus VASP reactivity index (PR
as RPA 14%. Solid circles represent prasugrel, and open circles represents clopigher risk of long-term adverse cardiovascular events. In egreement with their findings, we found a consistently high
raction of diabetic patients in the PD poor-responder
roups (Table 2). Despite a similar number of diabetic
atients in the treatment groups, there were very few
oor-responder diabetic patients in the prasugrel group.
he problem of diabetic poor responders seems to be largely
onfined to the clopidogrel-treated patients. This observa-
ion is consistent with the effect on clinical outcomes in
iabetic patients in the TRITON study, in whom prasugrel
educed the cardiovascular risk by 30% (2).
Similar to the overall PD poor-responder group, the
iabetic patient subpopulation had significantly lower levels
f circulating active thienopyridine metabolite (Fig. 5). The
iabetic patients did not differ in baseline ADP-stimulated
ggregation in the current study, but had an attenuated
hienopyridine effect after both LD and MD. However, the
esponsiveness to added AM was unaffected by the presence
f diabetes. Together these results indicate that PD poor
esponsiveness to clopidogrel in diabetic patients is attrib-
table to insufficient generation of AM, not to alterations in
latelet P2Y12 receptor function.
The reason that diabetic patients have lower levels of AM
s unclear. We are not aware of any effect of diabetes on
ytochrome P-450 activity reported in the literature. We
ould speculate an increased activity of esterases in diabetic
atients, which would convert more of the clopidogrel
ro-drug into inactive metabolite. This has been seen for
spirin resistance, in which increased activity of plasma
Responders Defined as RPA >14%
 0.001) in poor-responder subjects defined
l treatment. Abbreviations as in Figures 2 to 4.Poor
I%) (p
idogresterases hydrolyzed acetylsalicylic acid to a higher extent in
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Thienopyridine Responders December 9, 2008:1968–77atients with type 2 diabetes (34). Another possibility is that
educed gastric motility in diabetic patients could lead to
lower absorption of the pro-drugs or that alterations at the
egakaryocyte level changes platelet turnover and receptor
xpression.
onclusions
rasugrel treatment results in significantly fewer PD poor
esponders compared with clopidogrel after LD and
uring MD, even after the higher 600-mg clopidogrel
D. The impaired platelet inhibition in the clopidogrel
oor-responder groups and in diabetic patients reflects
ower plasma levels of AM and not differences in platelet
2Y12 receptor function.
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